Novartis’ Sandoz settles with Novo Nordisk for 2024 launch of third Victoza generic – Endpoints News

Although the patents on the active ingredient of Novo Nordisk’s GLP-1 blockbuster Victoza for Type 2 diabetes expire next year, the company agreed …